| Literature DB >> 30478888 |
Chen Chen1, Xiao Li2, Lisha Sun1, Sha Cao1, Yu Kang1, Liu Hong1, Yaodan Liang1, Guiying You1, Qing Zhang1.
Abstract
AIMS: In addition to giving optimal medical and device therapy, promoting self-care of chronic heart failure (CHF) patients also plays an important role in comprehensive disease management for better outcomes. The study was aimed to investigate whether short message service (SMS) would help to improve death or readmission-free survival and self-care behaviour in CHF patients. METHODS ANDEntities:
Keywords: Chronic heart failure; Composite endpoint; Self-care behaviour; Short message service; Structured telephone support
Mesh:
Year: 2018 PMID: 30478888 PMCID: PMC6352960 DOI: 10.1002/ehf2.12380
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Figure 1Sample message by SMS (in Chinese originally and in English for demonstration).
Figure 2Flow chart of the study.
Demographics and clinical characteristics among three groups (n = 767)
| Characteristic | SMS group ( | STS group ( | Control group ( |
|
|---|---|---|---|---|
| Age | 60 ± 15 | 62 ± 14 | 61 ± 15 | 0.189 |
| Gender, male | 145 (57.5) | 139 (54.5) | 149 (57.3) | 0.745 |
| NYHA III or IV | 175 (69.4) | 178 (69.8) | 172 (66.2) | 0.617 |
| Cardiovascular risk profile | ||||
| Ischaemic heart disease | 47 (18.7) | 56 (22.0) | 55 (21.2) | 0.630 |
| Non‐ischaemic cardiomyopathy | 108 (42.9) | 95 (37.3) | 90 (34.6) | 0.148 |
| Valvular heart diseases | 66 (26.2) | 69 (27.1) | 75 (28.8) | 0.789 |
| Hypertension | 82 (32.5) | 93 (36.5) | 94 (36.2) | 0.588 |
| Diabetes mellitus | 70 (27.8) | 77 (30.2) | 92 (35.4) | 0.164 |
| COPD | 31 (12.3) | 41 (16.1) | 29 (11.2) | 0.226 |
| Chronic renal disease | 26 (10.3) | 32 (12.5) | 23 (8.8) | 0.388 |
| Systolic blood pressure, mmHg | 113 ± 15 | 114 ± 14 | 114 ± 15 | 0.508 |
| Diastolic blood pressure, mmHg | 70 ± 10 | 69 ± 10 | 69 ± 10 | 0.326 |
| Heart rate | 83 ± 20 | 84 ± 22 | 84 ± 23 | 0.998 |
| Atrial fibrillation | 108 (42.9) | 102 (40.0) | 120 (46.2) | 0.369 |
| LVEF, % | 44 ± 17 | 42 ± 16 | 45 ± 17 | 0.139 |
| Pharmacotherapy | ||||
| ACEI/ARB | 127 (50.4) | 139 (54.5) | 140 (53.8) | 0.609 |
| Beta‐blocker | 162 (64.3) | 145 (56.9) | 170 (65.4) | 0.096 |
| Aldosterone antagonists | 163 (64.7) | 190 (74.5) | 181 (69.6) | 0.055 |
| Diuretics | 195 (77.4) | 208 (81.6) | 193 (74.2) | 0.134 |
| Digoxin | 114 (45.2) | 106 (41.6) | 105 (40.4) | 0.513 |
| Device therapy | ||||
| ICD | 13 (5.2) | 13 (5.1) | 17 (6.5) | 0.724 |
| CRT or CRT‐D | 17 (6.7) | 29 (11.4) | 11 (4.2) | 0.007 |
| Laboratory test | ||||
| Hb, g/L | 132 ± 24 | 132 ± 23 | 131 ± 23 | 0.858 |
| Hct, % | 40.7 ± 6.6 | 40.9 ± 6.7 | 40.4 ± 6.8 | 0.753 |
| Cr, μmol/L | 104.6 ± 62.7 | 105.0 ± 60.9 | 97.1 ± 44.6 | 0.625 |
| BUN, mmol/L | 8.2 ± 3.9 | 8.7 ± 4.6 | 8.1 ± 4.2 | 0.287 |
| NT‐proBNP, pg/mL | 3223 (1544, 8205) | 3765 (1323, 8032) | 3120 (1626, 7006) | 0.878 |
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; Cr, creatinine; CRT, cardiac resynchronization therapy; CRT‐D, cardiac resynchronization therapy with defibrillator; Hb, haemoglobin; Hct, haematocrit; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.
Composite endpoint, death, and readmission rate among three groups
| SMS | STS | Control | OR (95% CI) | |||
|---|---|---|---|---|---|---|
|
|
|
| SMS vs. control | STS vs. control | SMS vs. STS | |
| Composite endpoint | 104 (41.3) | 93 (36.5) | 131 (50.4) | 0.819 (0.677, 0.991) | 0.724 (0.591, 0.886) | 1.132 (0.909, 1.409) |
| Death | 26 (10.3) | 22 (8.6) | 28 (10.8) | 0.958 (0.578, 1.587) | 0.801 (0.471, 1.362) | 1.196 (0.697, 2.053) |
| Readmission | 85 (33.7) | 78 (30.6) | 111 (42.7) | 0.790 (0.632, 0.988) | 0.716 (0.568, 0.904) | 1.103 (0.856, 1.421) |
| HF‐related event | 69 (27.4) | 62 (24.3) | 83 (31.9) | 0.858 (0.656, 1.122) | 0.762 (0.576, 1.008) | 1.126 (0.838, 1.513) |
| HF‐related death | 21 (8.3) | 18 (7.1) | 24 (9.2) | 0.903 (0.516, 1.580) | 0.765 (0.426, 1.374) | 1.181 (0.645, 2.162) |
| HF‐related readmission | 54 (21.4) | 49 (19.2) | 66 (25.4) | 0.844 (0.616, 1.157) | 0.757 (0.546, 1.050) | 1.115 (0.790, 1.575) |
CI, confidence interval; OR, odds ratio.
P = 0.039.
P = 0.001.
P = 0.037.
P = 0.004.
Figure 3Kaplan–Meier survival analysis among three groups.
Univariate analysis and multivariate analysis on composite endpoint
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Age, 10 years | 1.038 | 0.963~1.120 | 0.327 | |||
| Gender, male | 0.900 | 0.724~1.119 | 0.342 | |||
| Diabetes mellitus | 1.163 | 0.926~1.460 | 0.194 | |||
| COPD | 1.049 | 0.763~1.441 | 0.770 | |||
| Chronic renal disease | 1.665 | 1.226~2.262 | 0.001 | 1.327 | 0.883~1.994 | 0.173 |
| Anaemia | 1.259 | 0.973~1.629 | 0.080 | 1.052 | 0.744~1.485 | 0.776 |
| Atrial fibrillation | 1.351 | 1.088~1.677 | 0.007 | 1.291 | 1.029~1.620 | 0.028 |
| LVEF, 10% increase | 1.079 | 1.021~1.151 | 0.021 | 1.080 | 1.006~1.160 | 0.034 |
| Heart rate, 10 b.p.m. increase | 1.041 | 0.991~1.094 | 0.109 | |||
| Systolic blood pressure, 10 mmHg | 0.962 | 0.893~1.035 | 0.296 | |||
| Cr, 10 μmol/L | 1.019 | 1.003~1.035 | 0.018 | 0.982 | 0.956~1.010 | 0.203 |
| BUN, 5 mmol/L | 1.250 | 1.116~1.400 | <0.001 | 1.221 | 1.034~1.442 | 0.019 |
| NT‐proBNP, 1000 pg/mL | 1.025 | 1.013~1.037 | <0.001 | 1.023 | 1.009~1.037 | 0.001 |
| Hct, 10% | 0.863 | 0.732~1.019 | 0.082 | 0.984 | 0.794~1.219 | 0.881 |
| Group | 0.009 | 0.034 | ||||
| SMS vs. control | 0.759 | 0.587~0.982 | 0.036 | 0.795 | 0.611~1.035 | 0.088 |
| STS vs. control | 0.673 | 0.515~0.877 | 0.003 | 0.705 | 0.536~0.926 | 0.012 |
HR, hazard ratio. Other abbreviations as in Tables 1 and 2.
Rates of self‐care behaviour among three groups
| SMS | STS | Control | RR (95% CI) | |||
|---|---|---|---|---|---|---|
|
|
|
| SMS vs. control | Phone vs. control | SMS vs. phone | |
| Medication compliance | 165 (78.9) | 179 (81.4) | 139 (69.5) | 1.136 (1.012, 1.275) | 1.171 (1.047, 11.309) | 0.970 (0.883, 11.066) |
| Weight monitor | 30 (14.4) | 45 (20.5) | 27 (13.5) | 1.063 (0.656, 11.722) | 1.515 (0.979, 12.346) | 0.702 (0.460, 11.070) |
| Salt restriction | 157 (75.1) | 159 (72.3) | 135 (67.5) | 1.113 (0.983, 11.260) | 1.071 (0.944, 11.215) | 1.039 (0.928, 11.164) |
| water restriction | 148 (70.8) | 164 (74.5) | 123 (61.5) | 1.151 (1.001, 11.324) | 1.212 (1.060, 11.386) | 0.950 (0.846, 11.067) |
| Exercise | 130 (62.2) | 132 (60.0) | 111 (55.5) | 1.121 (0.952, 11.319) | 1.081 (0.917, 11.274) | 1.037 (0.891, 11.206) |
RR, relative risk.
P = 0.029.
P = 0.005.
P = 0.046.
P = 0.004.
Minnesota Living with Heart Failure Questionnaire among three groups
| Variables | SMS | STS | Control |
|
|---|---|---|---|---|
| Total score at baseline | 62.9 ± 22.2 | 61.0 ± 23.2 | 61.9 ± 23.3 | 0.455 |
| Total score at 180 day follow‐up | 27.7 ± 16.1 | 25.5 ± 16.6 | 26.7 ± 16.8 | 0.526 |
| Changes in total score | 34.4 ± 23.9 | 33.7 ± 23.5 | 35.0 ± 25.5 | 0.703 |